Guideline Recommendations for Glucocorticoid‑Intolerant Polymyalgia Rheumatica

Glucocorticoid‑Sparing Pharmacologic Options

Methotrexate (7.5–10 mg/week) is the only conventional DMARD conditionally recommended by the EULAR/ACR guidelines for PMR and should be introduced early in patients with glucocorticoid‑intolerant disease or high‑risk comorbidities (e.g., diabetes, osteoporosis with recent fracture, glaucoma, uncontrolled hypertension, cardiovascular disease, chronic infections)【1】【4】.
Methotrexate is advised for patients at high risk of relapse or prolonged therapy (female sex, peripheral inflammatory arthritis, baseline ESR > 40 mm/h)【4】【5】.
Methotrexate should be added when patients experience glucocorticoid‑related adverse events or have disease relapse/inadequate response to glucocorticoids【2】【3】【6】.
Evidence for methotrexate is mixed, but the conditional recommendation is based on its glucocorticoid‑sparing potential【1】【2】 (strength: conditional).
Clinical dosing evidence comes from PMR trials using oral methotrexate 7.5–10 mg/week【1】【2】【3】.

Tocilizumab is the most extensively studied biologic for PMR, showing superior efficacy versus placebo in achieving sustained remission and reducing glucocorticoid exposure【7】 (strength: strong efficacy signal).
Phase III GCA trials and phase II/III PMR trials demonstrated higher remission rates and better glucocorticoid‑sparing with tocilizumab compared with placebo【7】.
Tocilizumab (and methotrexate) have not yet shown a reduction in glucocorticoid‑related adverse outcomes, although they lower cumulative glucocorticoid dose【7】.
Sarilumab, another IL‑6 receptor antagonist, achieved higher remission than placebo in a phase III trial (terminated early due to COVID‑19), indicating emerging efficacy【7】.

Intramuscular methylprednisolone 120 mg every 3 weeks can be used as an alternative to oral glucocorticoids in patients where lower cumulative exposure is desired (especially women with difficult hypertension, diabetes, osteoporosis, or glaucoma)【1】【2】【4】【8】.
Evidence is limited to a single RCT, which showed no reduction in glucocorticoid‑related adverse events except for weight gain; long‑term benefits are unknown and the formulation is not universally available【4】【8】 (strength: conditional, low‑quality evidence).

An individualized exercise program should be instituted to preserve muscle mass, maintain function, and lower fall risk in older or frail patients on long‑term glucocorticoids【1】【2】【3】【6】.

TNF‑α inhibitors are strongly recommended against for isolated PMR because they have demonstrated no efficacy【1】【2】【3】【6】.
Chinese herbal preparations (Yanghe and Biqi capsules) are also strongly advised against for PMR patients【1】【2】【3】.

Patients should be reviewed every 4–8 weeks during the first year【1】【6】【5】.
At each visit, assess disease activity, inflammatory markers (e.g., ESR/CRP), and any adverse events【1】【3】【5】.

Absolute glucocorticoid contraindication or severe intolerance → consider off‑label tocilizumab monotherapy【2】.
If minimal glucocorticoid exposure is acceptable → start the lowest effective oral dose (≈12.5 mg prednisone equivalent) and add methotrexate 7.5–10 mg/week immediately【1】【2】【3】.
If oral glucocorticoids are problematic → intramuscular methylprednisolone may be used【1】【4】【8】.
Failure of methotrexate or emergence of glucocorticoid toxicity → add tocilizumab or sarilumab【7】.

NSAIDs should not be used as primary therapy for PMR; they are only acceptable for short‑term pain from other conditions【1】【3】【6】【5】.
Prompt specialist referral is essential for atypical presentations, high‑risk side‑effect profiles, or glucocorticoid resistance【5】.
Even with biologics, complete avoidance of glucocorticoids is rarely achievable; the therapeutic goal is minimization, not elimination【7】.